Aktis Oncology's IPO

Q: When does the lock-up end?

Aktis Oncology's IPO lock-up ends Jul 7, 2026. Its final prospectus says: “180 days after the date of this prospectus.”

Listed Jan 9, 2026 at $18 on Nasdaq as AKTS.

Offer price

$18

Market cap

$945M

17,650,000

Today 16% below its $18 offer price; its first day closed +24.4%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See AKTS ranked, live

See it live, free until Friday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Jan 9, 2026.

What does Aktis Oncology do?

“We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.”

From its final prospectus (424B4), filed Jan 9, 2026

Aktis Oncology's facts, each with its source
Fact	Aktis Oncology
Incorporated	Delaware, 2020From its final prospectus (424B4) of Jan 9, 2026
Headquarters	Boston, MassachusettsFrom its final prospectus (424B4) of Jan 9, 2026
Employees	76 full-time, as of September 30, 2025From its final prospectus (424B4) of Jan 9, 2026
Website	aktisoncology.comFrom its final prospectus (424B4) of Jan 9, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Aktis Oncology's facts, each with its source
Fact	Aktis Oncology
Shares offered	17,650,000From the final prospectus (424B4) filed Jan 9, 2026
Offer price	$18 a shareFrom the final prospectus (424B4) filed Jan 9, 2026
Raised at that price	$318 millionFrom the final prospectus (424B4) filed Jan 9, 2026
Underwriters' discount	$22.2 millionFrom the final prospectus (424B4) filed Jan 9, 2026
Underwriters' option	2,647,500 more sharesFrom the final prospectus (424B4) filed Jan 9, 2026
Underwriters	J.P. Morgan, BofA Securities, Leerink Partners, and TD CowenFrom the final prospectus (424B4) filed Jan 9, 2026, as its cover names them
Exchange	Nasdaq Global Select Market, as AKTSFrom the final prospectus (424B4) filed Jan 9, 2026
Shares outstanding after	52,522,279From the final prospectus (424B4) filed Jan 9, 2026
Market cap at the offer price	$945 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Aktis Oncology's facts, each with its source
Fact	Aktis Oncology
Revenue	None from product sales yetFrom its final prospectus (424B4) of Jan 9, 2026: it has not generated any revenues from product sales
Cash	$246 million, as of September 30, 2025From its final prospectus (424B4) of Jan 9, 2026: cash, cash equivalents and marketable securities
Last preferred stock	Series B preferredFrom its final prospectus (424B4) of Jan 9, 2026

Every date of Aktis Oncology's IPO

Aktis Oncology's IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Dec 19, 2025	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Jan 7, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Jan 8, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed Jan 9, SEC EDGAR	Jan 8, 2026	final prospectus (424B4), filed Jan 9, SEC EDGAR
First tradeMassive's IPO calendar	Jan 9, 2026	Massive's IPO calendar
Lock-up endsfinal prospectus, SEC EDGAR: “180 days after the date of this prospectus”	Jul 7, 2026	final prospectus, SEC EDGAR: “180 days after the date of this prospectus”

How did its first days trade?

From its daily bars, each close against its $18 offer price.

Aktis Oncology's first sessions
Day	Open	Close	From the offer
Jan 9	$27	$22.40	+24.4%
Jan 12	$22.45	$21.75	+20.8%
Jan 13	$23.05	$21.35	+18.6%
Jan 14	$21.20	$20.81	+15.6%
Jan 15	$21.06	$20.56	+14.2%

What is Aktis Oncology's Quality Score?

Below Average

207 trading days so far.

AKTS's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetexchange registration Oct 29
KAT Construction ServicesNYSE American: KATX · No day yet	$5 to $7About $50.8M	$50.8Mat the midpoint	No day yetterms set Oct 29
Simwon AmericaNasdaq: SWA · No day yet	$20About $295M	$295Mat the midpoint	No day yetterms set Oct 28
AlopexxNYSE American · No day yet	$10 to $12About $91.3M	$91.3Mat the midpoint	No day yetterms set Oct 27
Regenlab USANasdaq · No day yet	$7	Not yet	No day yetterms set Oct 27
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Aktis Oncology IPO questions

When is Aktis Oncology's IPO?

Listed Jan 9, 2026 at $18 on Nasdaq as AKTS.

What is Aktis Oncology's IPO price?

Aktis Oncology's IPO priced at $18 a share, per its final prospectus of Jan 9, 2026.

How many shares is Aktis Oncology selling?

17,650,000 shares, and the underwriters may buy 2,647,500 more, per its final prospectus (424B4).

Who are the underwriters?

J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen, as the prospectus's cover names them.

When does the lock-up end?

Aktis Oncology's IPO lock-⁠up ends Jul 7, 2026. Its final prospectus says: “180 days after the date of this prospectus.”

Does Breakaway rate Aktis Oncology?

Aktis Oncology has a Quality Score of 1 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Aktis Oncology's price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 11 new listings ranked

See it live, free until Friday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and January 2026's listings.